Using Climate-HIV to describe real-world clinical outcomes for people living with HIV taking dolutegravir-based regimens.

"Declaration of conflicting interests: The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: C Okoli, A Paice, J van Wyk, and P Benn are employees of ViiV Healthcare and own stock in GlaxoSmithKline. M Radford was an employee of ViiV Healthcare at the time of the study. A Schwenk, J Barnes, A Darley, and S Munshi have nothing to disclose. M Myland and F Grimson are employees from IQVIA and have received grants from ViiV Healthcare. S Taylor has received grants from ViiV Healthcare, Gilead, and Merck. A Fox is employed by Nottingham University Hospitals NHS Trust, which received a grant from ViiV Healthcare before the conduct of the study to update clinical HIV databases. I Reeves has received grants from ViiV Healthcare. A Croucher is employed by the Jonathan Mann Clinic, Homerton University Hospital NHS Foundation Trust, which received a grant from ViiV Healthcare during the conduct of the study to update local patient records. N Boxall is employed by and has received personal fees from IQVIA."

"Funding: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by ViiV Healthcare."